Chimerix Starts Smallpox Trial

Chimerix has started a multidose trial with CMX001, an oral treatment for smallpox infection.

The trial will study the pharmacokinetics and safety of three doses of the drug given to healthy volunteers.

CMX001 is being developed for smallpox under a licensing agreement with Gilead Sciences and is funded by a $36.1 million grant awarded by the National Institutes of Allergy and Infectious Disease, Chimerix said.